[
    [
        {
            "time": "2021-12-31",
            "original_text": "2021版医保目录申报在即，约40款新药入围！预计明年1月落地执行",
            "features": {
                "keywords": [
                    "医保目录",
                    "新药",
                    "入围"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2021版医保目录申报在即，约40款新药入围！预计明年1月落地执行",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "恒瑞医药（600276.SH）：SHR1459片治疗原发性膜性肾病申报临床获批",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR1459",
                    "膜性肾病",
                    "临床获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药（600276.SH）：SHR1459片治疗原发性膜性肾病申报临床获批",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "恒瑞医药（600276.SH）：SHR-1701注射液两个新适应症获批临床",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR-1701",
                    "新适应症",
                    "临床获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药（600276.SH）：SHR-1701注射液两个新适应症获批临床",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "恒瑞医药：SHR1459片治疗原发性膜性肾病获批开展床试验",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR1459",
                    "膜性肾病",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：SHR1459片治疗原发性膜性肾病获批开展床试验",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "恒瑞医药：子公司SHR-1701注射液获批开展床试验",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR-1701",
                    "子公司",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：子公司SHR-1701注射液获批开展床试验",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "投入470 万元！国产眼药离上市又进一步",
            "features": {
                "keywords": [
                    "国产眼药",
                    "上市",
                    "研发资金"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "投入470 万元！国产眼药离上市又进一步",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "“花钱第一名”百济拟登科创板，首家“A+H+N”药企将诞生，募200亿继续砸研发",
            "features": {
                "keywords": [
                    "百济",
                    "科创板",
                    "A+H+N",
                    "募资",
                    "研发"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "“花钱第一名”百济拟登科创板，首家“A+H+N”药企将诞生，募200亿继续砸研发",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "主力尾盘抢筹化工、中药股 抛售生物科技板块",
            "features": {
                "keywords": [
                    "主力资金",
                    "化工",
                    "中药",
                    "生物科技",
                    "抛售"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "化工",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "主力尾盘抢筹化工、中药股 抛售生物科技板块",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "恒瑞医药告别“医药一哥”地位，市值较年内高点跌去三成",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "市值下跌",
                    "医药一哥"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药告别“医药一哥”地位，市值较年内高点跌去三成",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-29",
            "original_text": "A股融资融券日报：两融余额增加21.38亿元（6月29日）",
            "features": {
                "keywords": [
                    "两融余额",
                    "增加"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加21.38亿元（6月29日）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "恒瑞医药连续3日获北向资金净买入",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "北向资金",
                    "净买入"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药连续3日获北向资金净买入",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "第五批集采对恒瑞医药的影响",
            "features": {
                "keywords": [
                    "第五批集采",
                    "恒瑞医药",
                    "影响"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "第五批集采对恒瑞医药的影响",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]